Jeffrey R. Andolina, M.D., M.S.

Dr. Andolina is most interested in the treatment and comprehensive care for children with leukemia and lymphoma, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML), as well as the care for children with other cancers and blood diseases.

Dr. Andolina is the Director of Pediatric Bone Marrow Transplantation and has experience in treating both Leukemias, as well as non-malignant conditions including aplastic anemia and Immunodeficiencies. He has a particular interest in bone marrow transplant for patients with sickle cell anemia. In addition, Dr. Andolina has an interest in the adolescent and young adult population; he also cares for young adults undergoing bone marrow transplantation.

The University of Rochester is a member of multiple cooperative groups for pediatric cancer and pediatric bone marrow transplantation, including the Children's Oncology Group (COG), the Pediatric Blood and Marrow Tissue Consortium (PBMTC), and the Primary Immune Deficiency Treatment Consortium (PIDTC). Dr. Andolina is an investigator with each of these national groups and is the primary investigator for the PBMTC and PIDTC. He is on both the CML disease committee and also the cellular therapy committee of the COG. Together, we have over 75 clinical trials open and strive to have all front-line treatment studies open for our pediatric and young adult patients.

Please contact Dr. Andolina directly with any patient related or clinical related questions or concerns.

jeffrey_andolina@urmc.rochester.edu

Professional Background

Associate Professor of Pediatrics
Pediatric Hematology/Oncology/Stem Cell Transplantation
Director, Pediatric Bone Marrow Transplantation

Research

Dr. Andolina is interested in improving the outcome for children with cancer through offering enrollment on multi-institutional clinical trials through the Children's Oncology Group (COG) and Pediatric Blood and Marrow Tissue Consortium (PBMTC).

Dr. Andolina has a particular interest in Pediatric Bone Marrow Transplantation; Leukemia; Lymphoma; Neuroblastoma; Hematology, Oncology; Pediatric Hematology Oncology; Pediatric Oncology; Pediatric Cancer.

Dr. Andolina's research interests including improving bone marrow transplantation for children and young adults. He and colleagues have developed a clinical trial using haploidentical donors for bone marrow transplant, for those patients without fully matched sibling or matched unrelated donors. Haploidentical donors are "half matches," and almost all patients will have an available haploidentical donor, as all biological parents and half of full siblings will fall into this category.

Other research interests include evaluating reduced-intensity conditioning regimens for pediatric patients with malignant and non-malignant diseases, especially sickle cell anemia.

Dr. Andolina also performs laboratory research including the study of the gene expression profile of acute lymphoblastic leukemia cells, specifically evaluating gene expression changes which may confer survival advantages post-allogeneic hematopoietic stem cell transplantation.

Please contact Dr. Andolina directly with any patient related or clinical related questions or concerns.

jeffrey_andolina@urmc.rochester.edu

Credentials

Education

2004
MD | University of Virginia School of Medicine

Post-doctoral Training & Residency

07/01/2007 - 06/30/2010
Fellowship in Pediatric Hematology-Oncology at Northwestern University

06/21/2005 - 06/30/2007
Residency in Pediatrics at Northwestern University

06/21/2004 - 06/20/2005
Internship in Pediatrics at Northwestern University

VIEW ALL

Awards

2022
Faculty Teaching Award for Pediatrics
Sponsor: Medical student class of 2023, University of Rochester
Location: Rochester, NY

2022
Make a Difference
Sponsor: Adolescent and young adult group 13Thirty cancer connect
Location: Rochester, NY

2021
Faculty Teaching Award for Pediatrics
Sponsor: Medical Student Class of 2022
Location: University of Rochester

2020 - 2020
Faculty Teaching Award for Pediatrics, presented by medical student class of 2021
Sponsor: University of Rochester

2017 - 2018
Faculty Teaching Award for Pediatrics, presented by medical student class of 2019
Sponsor: Pediatric and Medicine-Pediatric Residents Class of 2018
Location: University of Rochester Medical Center

2017 - 2017
Early Career Distinguished Service Award
Sponsor: The Rochester Academy of Medicine
Location: Rochester, New York

2016 - 2016
Young Investigator Award, travel stipend
Sponsor: Pediatric Blood and Marrow Tissue Consortium (PBMTC)

2015 - 2016
Ruth A. Lawrence Academic Faculty Service Award
Location: University of Rochester Medical Center

2015 - 2016
Faculty Teaching Award
Sponsor: Pediatric and Medicine-Pediatric Residents Class of 2016
Location: University of Rochester Medical Center

2015 - 2015
ICare Bronze Star Award
Sponsor: University of Rochester Medical Center
Location: Rochester, New York

2014 - 2015
Faculty Teaching Award for Pediatrics presented by UR Medicine Medical Student Class of 2016
Sponsor: University of Rochester Medical Center
Location: Rochester, New York

2013 - 2014
Faculty Teaching Award for Pediatrics
Sponsor: Medical Student Class of 2013
Location: University of Rochester Medical Center

2013 - 2014
Alpha Omega Alpha (AOA)
Sponsor: University of Rochester Medical Center
Location: Inducted into AOA by Medical Student Class of 2013

2012 - Present
Children's Oncology Group Primary Investigator (PI)
Sponsor: University of Rochester Medical Center
Location: Rochester, New York

2007
Resident Teaching Award
Location: Children's Memorial Hospital, Chicago, IL

2007
A. Todd Davis Physician Award
Location: Children's Memorial Hospital

2005
Resident Teaching Award
Location: Children's Memorial Hospital, Chicago, IL

2004
Gold Humanism in Medicine Honor Society
Location: University of Virginia School of Medicine

VIEW ALL

Clinical Trials

A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) With Acute Leukemia or Myelodysplastic Syndrome (MDS)

Lead Researcher: Jeffrey R Andolina

This phase III trial compares hematopoietic (stem) cell transplantation (HCT) using mismatched related donors (haploidentical [haplo]) versus matched unrelated donors (MUD) in treating children, adolescents, and young adults with acute leukemia or myelodysplastic syndrome (MDS). HCT is considered standard of care treatment for patients with high-risk acute leukemia and MDS. In HCT, patients are given very high doses of chemotherapy and/or radiation therapy, which is intended to kill cancer cells that may be resistant to more standard doses of chemotherapy; unfortunately, this also destroys the normal cells in the bone marrow, including stem cells. After the treatment, patients must have a healthy supply of stem cells reintroduced or transplanted. The transplanted cells then reestablish the blood cell production process in the bone marrow. The healthy stem cells may come from the blood or bone marrow of a related or unrelated donor. If patients do not have a matched related donor, doctors do not know what the next best donor choice is. This trial may help researchers understand whether a haplo related donor or a MUD HCT for children with acute leukemia or MDS is better or if there is no difference at all.

View Study Details

Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995

Lead Researcher: Jeffrey R Andolina

Chronic granulomatous disease (CGD) is an inherited immune system abnormality in which bone marrow transplantation (BMT) has been shown to be curative. However the risks of transplantation are high and not all patients with CGD may need to undergo this high risk procedure. This study will determine the long term medical condition and daily functioning of participants with CGD after a transplant and if possible, compare these results to participants who do not undergo a transplant.

View Study Details

A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)

Lead Researcher: Jeffrey R Andolina

This study is a prospective evaluation of children with Severe Combined Immune Deficiency (SCID) who are treated under a variety of protocols used by participating institutions. In order to determine the patient, recipient and transplant-related variables that are most important in determining outcome, study investigators will uniformly collect pre-, post- and peri-transplant (or other treatment) information on all children enrolled into this study. Children will be divided into three strata: Stratum A: Typical SCID with virtual absence of autologous T cells and poor T cell function Stratum B: Atypical SCID (leaky SCID, Omenn syndrome and reticular dysgenesis with limited T cell diversity or number and reduced function), and Stratum C: ADA deficient SCID and XSCID patients receiving alternative therapy including PEG-ADA ERT or gene therapy. Each Group/Cohort Stratum will be analyzed separately.

View Study Details

Publications

Journal Articles

12/26/2022
Parisi R, Patel RR, Rood G, Bowden A, Turco G, Korones DN, Andolina JR, Comito M, Barth M, Weintraub L. "Multi-institution analysis of tumor mutational burden and outcomes in pediatric central nervous system tumor patients." Pediatric blood & cancer.. 2022 Dec 26; :e30139. Epub 2022 Dec 26.

11/28/2022
Dvorak CC, Haddad E, Heimall J, Dunn E, Cowan MJ, Pai SY, Kapoor N, Satter LF, Buckley RH, O'Reilly RJ, Chandra S, Bednarski JJ, Williams O, Rayes A, Moore TB, Ebens CL, Davila Saldana BJ, Petrovic A, Chellapandian D, Cuvelier GDE, Vander Lugt MT, Caywood EH, Chandrakasan S, Eissa H, Goldman FD, Shereck E, Aquino VM, Desantes KB, Madden LM, Miller HK, Yu L, Broglie L, Gillio A, Shah AJ, Knutsen AP, Andolina JP, Joshi AY, Szabolcs P, Kapadia M, Martinez CA, Parrot RE, Sullivan KE, Prockop SE, Abraham RS, Thakar MS, Leiding JW, Kohn DB, Pulsipher MA, Griffith LM, Notarangelo LD, Puck JM. "The diagnosis of severe combined immunodeficiency: Implementation of the PIDTC 2022 Definitions." The Journal of allergy and clinical immunology.. 2022 Nov 28; Epub 2022 Nov 28.

8/1/2022
Fries C, Evans AG, Cheon H, Korones DN, Loughran TP, Andolina JR. "Allogeneic Bone Marrow Transplant as a Cure for Refractory T-Cell Large Granular Lymphocytic Leukemia in an Adolescent." Journal of pediatric hematology/oncology.. 2022 Aug 1; 44(6):e960-e963. Epub 2021 Dec 29.

Books & Chapters

2023
Chapter Title: Lymphadenopathy
Book Title: Signs and Symptoms in Pediatrics
Author List: Weinberg GA, Segel GB, and Andolina JR
Published By: American Academy of Pediatrics 2023

2019
Chapter Title: Solid Tumors and Leukemias
Book Title: Avery's Neonatology Board Review
Author List: Andolina, JR
Published By: Elsevier 2019

2019
Chapter Title: White Blood Cells
Book Title: Avery's Neonatology Board Review
Author List: Andolina, JR
Published By: Elsevier 2019

VIEW ALL PUBLICATIONS

Reviews

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information.